Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Dyne Therapeutics Receives FDA Fast Track Designation For DYNE-251 For The Treatment Of Duchenne Muscular Dystrophy

By Benzinga Newsdesk
October 31, 7:30 AM
Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the

DYN

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

ESSA Collaborator Janssen Suspends Enrollment In Phase 1 Study Of EPI-7386 With Apalutamide Or Abiraterone Acetate Plus Prednisone

By Benzinga Newsdesk
October 31, 7:06 AM
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that

EPIX

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

KalVista Pharmaceuticals Announces Phase 1 Data For Orally Disintegrating Tablet Formulation Of Sebetralstat For Use In Hereditary Angioedema

By Benzinga Newsdesk
October 31, 6:46 AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive

KALV

Read More
1 minute read
  • Biotech
  • General
  • News

United Therapeutics Announces Top Line Data From The EXPEDITE Study Of Remodulin Induction Prior To Orenitram Therapy

By Benzinga Newsdesk
October 31, 6:05 AM
short induction of Remodulin® (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram® (treprostinil) extended-release tablets than patients who did not have a Remodulin

UTHR

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

FDA Defers Action On Amicus Therapeutics’ Much Awaited Pompe Disease Therapy

By Vandana Singh
October 31, 5:42 AM
The FDA deferred action on Amicus Therapeutics Inc’s (NASDAQ:FOLD) Biologics License Application (BLA) for cipaglucosidase alfa, the biologic component of AT-GAA for…

FOLD

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Small Cap
  • Trading Ideas

FDA’s AdComm Gives Thumbs Down To Pediatric Cancer Therapy

By Vandana Singh
October 31, 5:34 AM
FDA's Oncologic Drugs Advisory Committee (ODAC) raised concerns regarding the efficacy of Y-mAbs Therapeutics Inc's (NASDAQ: YMAB) potential pediatric neuroblastoma treatment, omburtamab.

YMAB

Read More
3 minute read
  • Biotech
  • FDA
  • General
  • News

U.S. FDA Defers Action On Filing For AT-GAA In Late-Onset Pompe Disease

By Benzinga Newsdesk
October 28, 4:02 PM
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date Company is Now Actively Engaged with the Agency to

FOLD

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Penny Stocks
  • Small Cap

Inovio Pharma Stops Work On INO-4800 As COVID-19 Heterologous Booster

By Vandana Singh
October 28, 12:37 PM
Inovio Pharmaceuticals Inc (NASDAQ:INO) discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Jacqueline Shea, CEO…

INO

Read More
1 minute read
  • Biotech
  • Earnings
  • Financing
  • General
  • Guidance
  • Health Care
  • Movers
  • News
  • Offerings
  • Trading Ideas

PTC Therapeutics Gets $1B Funding From Blackstone, Shares Fall

By Vandana Singh
October 28, 11:08 AM
PTC Therapeutics Inc (NASDAQ:PTCT) entered into a strategic financing collaboration with Blackstone Inc (NYSE:BX). As part of the collaboration, Blackstone Life Sciences and…

BX

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Price Target
  • Trading Ideas
  • Upgrades

Analysts Turn Bullish On Gilead After Q3 Earnings Surpass Expectations

By Vandana Singh
October 28, 10:08 AM
Thursday, Gilead Sciences Inc (NASDAQ:GILD) reported Q3 revenue decreased 5% Y/Y to $7.04 billion, which beat average analyst estimates of $6.12…

GILD

Posts pagination

Previous 1 … 644 645 646 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service